Postdoctoral Fellow at Xiamen University, China
Dr. Syed Faheem Askari Rizvi is an Assistant Professor and Associate Researcher with extensive expertise in medicinal chemistry, analytical chemistry, and bioanalytical chemistry. With a Ph.D. from Lanzhou University, China, and postdoctoral research at Xiamen University, he has cultivated a robust research profile in chemical synthesis, nanomedicine, and dual-imaging diagnostics. His work emphasizes peptide-drug conjugates, click-chemistry, and radiopharmaceuticals, contributing significantly to cancer therapeutics and diagnostic advancements. Dr. Rizvi’s hands-on proficiency with advanced analytical tools like HPLC, LC-MS, NMR, and fluorescence spectroscopy complements his research in synthetic chemistry and bioanalytical applications. He is a highly motivated and detail-oriented professional, passionate about multidisciplinary collaborations that drive clinical translation of novel therapeutics. His academic journey is enriched with several high-impact publications in prestigious journals, reflecting his commitment to scientific excellence. Dr. Rizvi is recognized for effective project management, strategic problem-solving, and mentoring emerging scientists. His long-term objective is to lead innovative research initiatives that bridge laboratory discoveries with real-world medical solutions, ultimately enhancing patient care. Dedicated to continual learning and leadership, he is poised to contribute meaningfully to academic and research institutions worldwide, fostering a dynamic environment for scientific innovation and technological advancement.
Professional Profiles
Education
Dr. Rizvi’s academic achievements demonstrate a steadfast commitment to chemical and biomedical sciences. He earned his Ph.D. in Chemistry (Analytical/Bioanalytical specialization) from Lanzhou University, China (2018–2021), where he graduated with Grade A distinction. Prior to this, he completed his M.Phil. in Chemistry (Analytical/Inorganic and Radiopharmaceutical Chemistry) with a CGPA of 3.49/4.00 from Government College University, Faisalabad, Pakistan (2010–2012). His foundational education includes a B.S. (Honors) in Chemistry (Analytical/Physical Chemistry) from the University of Sargodha, Pakistan (CGPA 2.97/4.00, 2006–2010). Early education in science was completed at Government M.A.O College Lahore for his Foundation of Science (F.Sc., Pre-Engineering, 1st Division, 2004–2006), and Matriculation with a Science focus from BISE Lahore (1st Division, 2002–2004). To strengthen his global academic capabilities, he also undertook the IELTS examination, achieving an overall score of 6.0 (Speaking 6.5, Writing 6.5) between 2014 and 2016. Each stage of his education sharpened his analytical thinking, experimental skills, and scientific communication, laying a strong foundation for his future research pursuits. His educational background reflects a trajectory characterized by a passion for innovation and rigorous scientific training that underpins his successful academic and professional career.
Professional Experience
Throughout his dynamic career, Dr. Rizvi has held several academic and research positions, blending teaching excellence with innovative scientific contributions. Currently, he serves as a Postdoctoral Fellow under the Talented Young Scientist Program (TYSP) at the School of Public Health, Xiamen University, China (Sept. 2024–present). Earlier, he completed a postdoctoral fellowship under the High-Level Foreign Talents Program at Lanzhou University (March 2022–May 2024), where he contributed to medicinal chemistry and bioanalytical research. Parallel to his research career, he has served as an Assistant Professor in Bioanalytical Chemistry at the Institute of Molecular Biology and Biotechnology (IMBB), University of Lahore, Pakistan (March 2021–present). His earlier teaching experience includes a Senior Lecturer position at Punjab Group of Colleges, Rawalpindi (2017–2018) and leadership roles as Lecturer and Head of Department at Punjab Group of Colleges, Kamoki (2013–2015). As a Research Associate at Government College University Faisalabad (2015–2017), he conducted critical research in nuclear medicine. Dr. Rizvi also has industry experience as an R&D Officer at EVYOL Group, further enriching his applied science perspective. His career reflects a seamless integration of academia, research, and practical applications, making him a versatile asset to any scientific or educational institution.
Research Interests
Dr. Rizvi’s research interests span a multidisciplinary spectrum at the intersection of chemistry, nanotechnology, and biomedical sciences. He is deeply engaged in chemical synthesis, focusing on novel small peptide analogs, multistep linker synthesis, and Cu-catalyzed click chemistry for creating peptide-drug conjugates with enhanced therapeutic efficacy. His work in radiopharmaceutical development targets β/γ-conjugated probes for SPECT/CT imaging, enhancing cancer diagnosis and treatment strategies. Dr. Rizvi is particularly fascinated by nanomedicine innovations, engineering self-assembled nanoparticles for targeted drug delivery and imaging-guided theranostics. He explores receptor-mediated tumor targeting peptides and dual-modal optical-radionuclide imaging platforms for precise tumor visualization and therapy. His research emphasizes translating lab-scale chemical advances into clinically viable diagnostic and therapeutic solutions. In addition, he actively investigates protein purification and characterization using advanced biochemical techniques such as CLSM, FACS, and Western blotting. Dr. Rizvi aims to contribute to personalized medicine by designing biomolecule-drug conjugates that achieve higher selectivity, minimized side effects, and improved patient outcomes. His future research ambitions center around integrating cutting-edge chemical tools with biological systems to pioneer smart therapeutics and diagnostic tools, ultimately bridging the gap between chemistry and medicine.
Research Skills
Dr. Rizvi possesses a highly diverse and advanced set of research skills honed through rigorous academic and laboratory training. His chemical synthesis expertise includes multistep organic synthesis, development of enzymatically cleavable linkers, and Cu-catalyzed click chemistry for constructing peptide-drug conjugates. He is adept at using modern instrumentation, mastering techniques like HPLC, LC-MS, HR-MS, NMR, FT-IR, TEM, and fluorescence spectroscopy for compound characterization and data interpretation. Dr. Rizvi has demonstrated significant proficiency in radiopharmaceutical synthesis for nuclear imaging applications and possesses hands-on experience in in-vitro/in-vivo evaluation models for cancer therapy. He is skilled in dual-imaging technique development, combining optical and radionuclide imaging to enhance diagnostic accuracy. His biochemical skills include protein extraction and purification from human serum albumin, plasma, cell lysates, and tissue homogenates, followed by their characterization using state-of-the-art techniques like confocal microscopy, flow cytometry, and Western blotting. Additionally, he maintains a strong focus on quality control/assurance practices adhering to good scientific procedures. Dr. Rizvi’s integrated expertise allows him to manage complex research projects independently, from conceptualization to experimental execution and result analysis. These competencies enable him to contribute meaningfully to interdisciplinary research teams and foster innovation across chemical biology, nanotechnology, and clinical diagnostics.
Awards and Honors
Dr. Rizvi’s scientific excellence has been recognized through prestigious awards and fellowships. He was selected as a Fellow under the Talented Young Scientist Program (TYSP) by the Chinese government, a testament to his outstanding research capabilities and potential for leadership in scientific innovation. Additionally, he received the High-Level Foreign Talents Fellowship at Lanzhou University, China, where he contributed significantly to projects on peptide-drug conjugates and radiopharmaceuticals for cancer diagnosis. His research articles have been published in top-tier journals such as Biomaterials, Medicinal Research Reviews, ACS Pharmacology & Translational Science, and Applied Biochemistry and Biotechnology, collectively reflecting a cumulative impact factor exceeding 96 for first-author publications and 129 for co-authored works. Notably, his paper in Drug Delivery and Translational Research was awarded Best Article of the Issue (July 2022). His international publication record, coupled with participation in cutting-edge projects, highlights his role as a leading emerging scientist in chemical biology and nanomedicine. These recognitions underscore his dedication to advancing research excellence and strengthening global scientific collaborations, paving the way for his continued contributions to high-impact research and academia.
Conclusion
Dr. Syed Faheem Askari Rizvi stands out as a dynamic and accomplished researcher, educator, and scientific innovator. His robust background in medicinal and analytical chemistry, combined with extensive experience in chemical synthesis, nanoparticle development, and biomedical imaging, positions him at the forefront of translational research. Through his leadership in numerous research projects and his consistent publication record in high-impact journals, he has demonstrated an unwavering commitment to advancing scientific knowledge and improving therapeutic outcomes. Dr. Rizvi’s broad skill set, including advanced analytical instrumentation, protein biochemistry, and theranostic agent development, makes him a versatile contributor across multiple disciplines. His proactive approach to mentorship, project management, and cross-disciplinary collaboration enables him to inspire and lead future scientists toward impactful discoveries. Looking forward, Dr. Rizvi aims to expand his research frontiers in precision medicine and nanotechnology, with a vision to bridge basic science and clinical application. His strong ethical standards, collaborative spirit, and innovative mindset ensure that he will continue to make significant contributions to the scientific community and beyond, driving meaningful change in healthcare technologies worldwide.
Publications Top Notes
-
Title:
Next-Generation Oral Ulcer Management: Integrating Cold Atmospheric Plasma (CAP) with Nanogel-Based Pharmaceuticals for Inflammation Regulation
Authors: Yanfen Zheng, Ziqi Zhuang, Renwu Zhou, Yun Zeng, Peiyu Wang
Year: 2025
-
Title:
Engineering Peptide Drug Therapeutics through Chemical Conjugation and Implication in Clinics
Authors: Syed Faheem Askari Rizvi, Haixia Zhang, Quan Fang
Year: 2024
Citations: 10
-
Title:
Removal and Detection of Phenols through an SPE-HPLC Method Using Microporous Organic Networks as Adsorbent
Authors: Azam Ali, Huipeng Sun, Syed Faheem Askari Rizvi, Nana Ding, Haixia Zhang
Year: 2024
Citations: 2
-
Title:
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Authors: Syed Faheem Askari Rizvi, Linjie Zhang, Haixia Zhang, Quan Fang
Year: 2024
Citations: 16